Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Metformin improves peripheral insulin sensitivity in overweight adolescents with T1D

13 Jul 2019

Treatment with metformin may improve whole-body and peripheral insulin resistance (IR) in youth who are overweight/obese with type 1 diabetes (T1D), according to a study.

This double-blind, multicentre, placebo-controlled clinical trial was conducted at eight sites of the T1D Exchange Clinic Network and included a subset of individuals aged 12–19 years with T1D from a larger trial. The inclusion criteria were body mass index ≥85th percentile, HbA1c 7.5–9.9 percent and insulin dosing ≥0.8 U/kg/d.

Participants were randomly assigned to 3 months of metformin (n=19) or placebo (n=18) and underwent a three-phase hyperinsulinaemic euglycaemic clamp with glucose and glycerol isotope tracers to examine tissue-specific IR before and after treatment.

The authors measured peripheral insulin sensitivity, endogenous glucose release and lipolysis rate before and after metformin or placebo therapy.

Differences in change in insulin sensitivity were detected in favour of the metformin vs the placebo arm vis-à-vis whole-body IR (change in glucose infusion rate, 1.3 mg/kg/min, 0.1–2.4; p=0.03) and peripheral IR (change in metabolic clearance rate, 0.923 dL/kg/min, –0.002 to 1.867; p=0.05).

Metformin showed no influence on insulin suppression of endogenous glucose release (p=0.12). In addition, adipose IR could not be measured with traditional methods in this highly IR population.

“T1D in adolescence is characterized by insulin deficiency and IR, both thought to increase cardiovascular disease risk,” the authors said. “We previously demonstrated that adolescents with T1D have adipose, hepatic and muscle IR, and that metformin lowers daily insulin dose, suggesting improved IR.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.